To analyze various innovative approaches in the supportive therapy of patients with thalassemia and to summarize the efficacy of different biomedical interventions from Randomized Controlled Trials (RCT).
Methods
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines and registered in PROSPERO (CRD420251163054). A comprehensive literature search was conducted across four major databases: Scopus, PubMed, ScienceDirect, and Sage Journals. The inclusion criteria for this review involve patients with thalassemia, focus on the supportive therapy of thalassemia, conducted in healthcare settings, and employ a RCT design. The literature quality was evaluated using the Joanna Briggs Institute (JBI) tool for RCT. The data were synthesized using a narrative synthesis approach.
Results
From 2,394 records, 13 articles were identified. Luspatercept and Thalidomide were found to be the most effective in reducing transfusion dependence and increasing hemoglobin levels. For iron overload, Amlodipine and Spirulina significantly improved cardiac T2*, contributing to cardioprotection. Furthermore, Curcumin supplementation was shown to improve lipid metabolism and inhibit systemic inflammation. Meanwhile, therapies using Green Tea and Vitamin E were effective in reducing markers of cellular oxidative damage, with Green Tea also demonstrating dual efficacy in reducing serum ferritin (SF) and liver iron concentration (LIC).
Conclusion
Overall, new and adjuvant supportive therapies significantly support the biological management of patients with thalassemia. Further studies are required to integration between pharmacological therapies and nutraceutical approaches should be further explored to optimize improvements in hematological status, oxidative stress, and patients’ metabolic profiles.
Ahmed El-MasryH. M.El-ShanshoryM. R.Ali Hassan MahmoudA.-E.TolbaO. A.Mohammed Abd-Elmoety ElsharkawyH. A. (2020). Comparative therapeutic effect of the L-arginine and sildenafil on beta-thalassemia children with increased tricuspid regurgitant jet velocity. Pediatric Hematology Oncology Journal, 5(2), 25–29. https://doi.org/10.1016/j.phoj.2020.05.002
2.
AlafariH.AlenziF. Q. (2020). Biochemical and molecular analysis of the beta-globin gene and LCR region on Saudi β-thalassemia patients. Saudi Journal of Biological Sciences, 27(11), 3106–3112. https://doi.org/10.1016/j.sjbs.2020.08.044
3.
Al-MomenH.HusseinH. K.Al-AttarZ.HusseinM. J. (2020). Green tea influence on iron overload in thalassemia intermedia patients: A randomized controlled trial. F1000Research, 9, 1136. https://doi.org/10.12688/f1000research.25553.1
4.
AlSalhiM. S.AlGahtaniF. H.DevanesanS.VijmasiV. T.JeyaprakashK.AlSaeedA. H.MasilamaniV. (2014). Spectral detection of thalassemia: A preliminary study. Journal of Biomedical Science, 21(1), 26. https://doi.org/10.1186/1423-0127-21-26
5.
Ammad Ud DinM.AnwerF. (2020). Luspatercept for beta-thalassemia – A new horizon?European Oncology & Haematology, 16(1), 16–17. https://doi.org/10.17925/EOH.2020.16.1.16
6.
AngastiniotisM. (2024). Beta thalassemia: Looking to the future, addressing unmet needs and challenges. Annals of the New York Academy of Sciences, 1532(1), 63–72. https://doi.org/10.1111/nyas.15097
7.
AnsariS. H.LassiZ. S.KhowajaS. M.AdilS. O.ShamsiT. S. (2019). Hydroxyurea (hydroxycarbamide) for transfusion-dependent β-thalassaemia. Cochrane Database of Systematic Reviews, 2019(3), 1–14. https://doi.org/10.1002/14651858.CD012064.pub2
8.
BairdD. C.BattenS. H.SparksS. K. (2022). Alpha- and beta-thalassemia: Rapid evidence review. American Family Physician, 105(3), 272–280. 35289581.
9.
BettsM.FlightP. A.ParamoreL. C.TianL.MilenkovićD.ShethS. (2020). Systematic literature review of the burden of disease and treatment for transfusion-dependent β-Thalassemia. Clinical Therapeutics, 42(2), 322–337. https://doi.org/10.1016/j.clinthera.2019.12.003
10.
BhattacharjeeU.KhadwalA.ShafiqN.LadD.SharmaP.DasR.ShuklaP.JainA.PrakashG.MalhotraP. (2023). A phase 2 randomized controlled trial of single-agent hydroxyurea versus thalidomide among adult transfusion dependent β thalassemia patients. Indian Journal of Hematology & Blood Transfusion: An Official Journal of Indian Society of Hematology and Blood Transfusion, 39(2), 266–275. https://doi.org/10.1007/s12288-022-01620-3
11.
Bou-FakhredinR.De FranceschiL.MottaI.EidA. A.TaherA. T.CappelliniM. D. (2022). Redox balance in β-Thalassemia and sickle cell disease: A love and hate relationship. Antioxidants, 11(5), 967. https://doi.org/10.3390/antiox11050967
12.
CaldwellP. H.BennettT. (2020). Easy guide to conducting a systematic review. Journal of Paediatrics and Child Health, 56(6), 853–856. https://doi.org/10.1111/jpc.14853
13.
CampbellM.KatikireddiS. V.SowdenA.McKenzieJ. E.ThomsonH. (2018). Improving conduct and reporting of narrative synthesis of quantitative data (ICONS-Quant): Protocol for a mixed methods study to develop a reporting guideline. BMJ Open, 8(2), Article e020064. https://doi.org/10.1136/bmjopen-2017-020064
14.
CappelliniM. D.CohenA.PorterJ.TaherA.ViprakasitV. (Eds.), (2014). Guidelines for the management of transfusion dependent thalassaemia (TDT) (3rd ed.). Thalassaemia International Federation. https://www.ncbi.nlm.nih.gov/books/NBK269382/
ChenJ. M.ZhuW. J.LiuJ.WangG. Z.ChenX. Q.TanY.XuW. W.QuL. W.LiJ. Y.YangH. J.HuangL.CaiN.WangW.-D.HuangK.XuJ.-Q.LiG.-H.HeS.LuoT.-Y.HuangY.ZhouG. B. (2021). Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: A randomized clinical trial. Signal Transduction and Targeted Therapy, 6(1), 405. https://doi.org/10.1038/s41392-021-00811-0
17.
ElalfyM. S.HamdyM.AdlyA.EbeidF. S. E.TeminN. T.RozovaA.LeeD.FradetteC.TrictaF. (2023). Efficacy and safety of early-start deferiprone in infants and young children with transfusion-dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double-blind, placebo-controlled, clinical trial (START). American Journal of Hematology, 98(9), 1415–1424. https://doi.org/10.1002/ajh.27010
El-HaggarS. M.El-ShanshoryM. R.El-shafeyR. A.DabourM. S. (2018). Decreasing cardiac iron overload with amlodipine and spirulina in children with β-thalassemia. Pediatric Hematology Oncology Journal, 3(3), 64–69. https://doi.org/10.1016/j.phoj.2018.10.001
20.
ElLaboudyM. A.SaberM. M.AdlyA. A.IsmailE. A.IbrahimF. A.ElalfyO. M. (2025). Oxidative stress markers and tissue iron overload after 12-months vitamin E supplementation for children with transfusion-dependent β-thalassemia on different iron chelators: A randomized placebo-controlled trial. Clinical Nutrition, 50(7), 154–163. https://doi.org/10.1016/j.clnu.2025.05.003
21.
El-ShanshoryM.TolbaO.El-ShafieyR.MawlanaW.IbrahimM.El-GamasyM. (2019). Cardioprotective effects of spirulina therapy in children with beta-thalassemia major. Journal of Pediatric Hematology, 41(3), 202–206. https://doi.org/10.1097/MPH.0000000000001380
22.
FernandesJ. L.LoggettoS. R.VeríssimoM. P. A.FertrinK. Y.BaldanziG. R.FioravanteL. A. B.TanD. M.HigaT.MashimaD. A.PigaA.CoelhoO. R.CostaF. F.SaadS. T. (2016). A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Blood, 128(12), 1555–1561. https://doi.org/10.1182/blood-2016-06-721183
23.
GamaleldinM.AbrahamI.MeabedM.ElberryA.AbdelhalimS.WaggasD.HusseinR. (2023). Comparative effectiveness of adding omega-3 and manuka honey combination to conventional therapy in preventing and treating oxidative stress in pediatric β-thalassemia major—A randomized clinical trial. European Review for Medical and Pharmacological Sciences, 27(13), 6058–6070. https://doi.org/10.26355/eurrev_202307_32960
24.
GarbowskiM. W.UgidosM.RisueñoA.ShettyJ. K.SchwickartM.HermineO.PorterJ. B.ThakurtaA.VodalaS. (2024). Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia. American Journal of Hematology, 99(2), 182–192. https://doi.org/10.1002/ajh.27102
25.
HamadiA. A.FajerA. N. (2025). Potential effect of spirulina extracts on serum iron reduction: Possible application in cancer treatment. Asian Pacific Journal of Cancer Biology, 10(1), 47–55. https://doi.org/10.31557/apjcb.2025.10.1.47-55
26.
HamedE. M.MeabedM. H.AlyU. F.HusseinR. R. S. (2019). Recent progress in gene therapy and other targeted therapeutic approaches for beta thalassemia. Current Drug Targets, 20(16), 1603–1623. https://doi.org/10.2174/1389450120666190726155733
27.
HandayaniN. S. N.HusnaN.RahmilG.GhifariR. A.WidyawatiL.LesmanaI. (2021). Splice-site and frameshift mutations of β-Globin gene found in thalassemia carrier screening in yogyakarta special region, Indonesia. The Indonesian Biomedical Journal, 13(1), 55–60. https://doi.org/10.18585/inabj.v13i1.1406
28.
HariharanP.NadkarniA. (2021). Insight of fetal to adult hemoglobin switch: Genetic modulators and therapeutic targets. Blood Reviews, 49, Article 100823. https://doi.org/10.1016/j.blre.2021.100823
29.
HemprachitchaiN.PraneetponkangR.WongwerawattanakoonP.WongborisuthC.InnachaiP.KadegasemP.KhlangtanT.SriwantanaT.PhoonlapdachaP.DumrongwongsiriO.ChuansumritA.PattanapanyasatK.SirachainanN.SibmoohN.ChaichompooP.SongdejD. (2025). Measures of cellular oxidative damage following vitamin E supplementation in young patients with transfusion-dependent thalassemia: A double-blind randomized controlled trial. BMC Pediatrics, 25(1), 405. https://doi.org/10.1186/s12887-025-05741-2
KhaledA.SalemH. A.EzzatD. A.SeifH. M.RabeeH. (2019). A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major. Drug Design, Development and Therapy, 13, 2427–2436. https://doi.org/10.2147/DDDT.S211630
32.
KhandrosE.KwiatkowskiJ. L. (2019). Beta thalassemia: Monitoring and new treatment approaches. Hematology-Oncology Clinics of North America, 33(3), 339–353. https://doi.org/10.1016/j.hoc.2019.01.003
33.
KavithaK.PadmajaA.SikandarB. J. (2024). Impact of SCOPE program on health-related quality of life and health status of children with thalassemia: A quasi-experimental study. Journal of Pediatric Hematology/Oncology Nursing, 41(3), 199–211. https://doi.org/10.1177/27527530231214542
34.
LalA.WongT.KeelS.PaganoM.ChungJ.KamdarA.RaoL.IkedaA.PuthenveetilG.ShahS.YuJ.VichinskyE. (2021). The transfusion management of beta thalassemia in the United States. Transfusion (Paris), 61(10), 3027–3039. https://doi.org/10.1111/trf.16640
35.
LiY.ZhangY.QinL.ShangH.LiP.XiaoB.YeY.XuX.ZhangX.WangL. (2023). Analysis of hematological indices and splenectomy rates in 2,130 patients with hemoglobin H diseases or β-Thalassemia. Acta Haematologica, 146(6), 458–464. https://doi.org/10.1159/000533233
36.
LongoF.TesioN.PiolattoA.FerreroG. B.PigaA. (2021). Luspatercept for the treatment of β-thalassemia: From preclinical research to clinical practice and beyond. Future Rare Diseases, 1(4), 664–671. https://doi.org/10.2217/frd-2021-0012
37.
Lopez-CortesO.Betancourt-NúñezA.OrozcoM. F. B.VizmanosB. (2022). Scoping reviews: A new way of evidence synthesis. Investigacion en Educacion Medica, 11(44), 98–104. https://doi.org/10.22201/fm.20075057e.2022.44.22447
38.
MaskoenA. M.RahayuN. S.ReniartiL.SusanahS.LaksonoB.FauziahP. N.ZadaA.HidayatD. S. (2017). Mutation spectrum of Î2-globin gene in thalassemia patients at Hasan Sadikin hospital—West Java Indonesia. Cellular & Molecular Biology, 63(12). Article 12. https://doi.org/10.14715/10.14715/cmb/2017.63.12.6
39.
Miri-AliabadG. (2025). Beta thalassemia: An overview of epidemiology, clinical features, diagnosis, and management. Avicenna Journal of Clinical Medicine, 31(4), 255–263. https://doi.org/10.32592/ajcm.31.4.255
40.
ModellB.DarlisonM. (2008). Global epidemiology of haemoglobin disorders and derived service indicators. Bulletin of the World Health Organization, 86(6), 480–487. https://doi.org/10.2471/blt.06.036673
41.
MokgalaboniK.PhoswaW. N.ModjadjiP.LebeloS. L. (2025). Curcumin therapy reduces iron overload and oxidative stress in beta-thalassemia: Findings from a meta-analytic study. Thalassemia Reports, 15(3), 7. https://doi.org/10.3390/thalassrep15030007
42.
NasseriE.MohammadiE.TamaddoniA.QujeqD.ZayeriF.ZandH. (2017). Benefits of curcumin supplementation on antioxidant status in β-Thalassemia major patients: A double-blind randomized controlled clinical trial. Annals of Nutrition & Metabolism, 71(3–4), 136–144. https://doi.org/10.1159/000479634
43.
OsataphanN.DumnilS.TantiworawitA.PunnachetT.HantrakunN.PiriyakhuntornP.RattanathammetheeT.HantrakoolS.Chai-AdisaksophaC.RattarittamrongE.NorasetthadaL.FanhchaksaiK.CharoenkwanP. (2023). The long-term efficacy in blood transfusions, hematologic parameter changes, and complications after splenectomy in patients with transfusion-dependent thalassemia. Transfusion and Apheresis Science: Official Journal of the World Apheresis Association: Official Journal of the European Society for Haemapheresis, 62(3), Article 103620. https://doi.org/10.1016/j.transci.2022.103620
44.
OuzzaniM.HammadyH.FedorowiczZ.ElmagarmidA. (2016). Rayyan—A web and mobile app for systematic reviews. Systematic Reviews, 5(1), 210. https://doi.org/10.1186/s13643-016-0384-4
45.
PintoV. M.ForniG. L. (2020). Management of iron overload in beta-thalassemia patients: Clinical practice update based on case series. International Journal of Molecular Sciences, 21(22), 8771. https://doi.org/10.3390/ijms21228771
46.
PughP.HemingwayP.ChristianM.HigginbottomG. (2018). Children’s, parents’ and other stakeholders’ perspectives on early dietary self-management to delay disease progression of chronic disease in children: A protocol for a mixed studies systematic review with a narrative synthesis. Systematic Reviews, 7(1), 20. https://doi.org/10.1186/s13643-017-0671-8
47.
RayS.SaikiaD.VashishtY.SharmaS.MeenaR. K.KumarM. (2024). Dyslipidemia and atherogenic indexes in children with transfusion-dependent thalassemia. Hematology, Transfusion and Cell Therapy, 46(4), 345–351. https://doi.org/10.1016/j.htct.2023.02.006
48.
SettakornK.HantrakoolS.PetiwathayakornT.HutachokN.TantiworawitA.CharoenkwanP.ChalorthamN.ChompupoungA.ParadeeN.KoonyosyingP.SrichairatanakoolS. (2023). A randomized placebo-controlled clinical trial of oral green tea epigallocatechin 3-gallate on erythropoiesis and oxidative stress in transfusion-dependent β-thalassemia patients. Frontiers in Molecular Biosciences, 10, Article 1248742. https://doi.org/10.3389/fmolb.2023.1248742
49.
ShahF.DwivediM. (2020). Pathophysiology and recent therapeutic insights of sickle cell disease. Annals of Hematology, 99(5), 925–935. https://doi.org/10.1007/s00277-020-03977-9
50.
SharmaA.JagannathV. A.PuriL. (2021). Hematopoietic stem cell transplantation for people with β‐thalassaemia. Cochrane Database of Systematic Reviews, 2021(4), Article 08708. https://doi.org/10.1002/14651858.CD008708.pub5
51.
ShethS.TaherA. T.CoatesT. D.KattamisA.CappelliniM. D. (2023). Management of luspatercept therapy in patients with transfusion-dependent β-thalassaemia. British Journal of Haematology, 201(5), 824–831. https://doi.org/10.1111/bjh.18801
52.
SolimanY.AbdelazizA.MouffokesA.AmerB. E.GoudyY. M.AbdelwahabO. A.BadawyM. M.DiabR. A.ElsharkawyA. (2023). Efficacy and safety of calcium channel blockers in preventing cardiac siderosis in thalassemia patients: An updated meta-analysis with trial sequential analysis. European Journal of Haematology, 110(4), 414–425. https://doi.org/10.1111/ejh.13919
53.
TabriziR.VakiliS.AkbariM.MirhosseiniN.LankaraniK. B.RahimiM.MobiniM.JafarnejadS.VahedpoorZ.AsemiZ. (2019). The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Phytotherapy Research: PT, 33(2), 253–262. https://doi.org/10.1002/ptr.6226
54.
TamaddoniA.NasseriE.MohammadiE.QujeqD.ZayeriF.ZandH.MirS. M.GholamiM. (2020). A double-blind randomized controlled trial of curcumin for improvement in glycemic status, lipid profile and systemic inflammation in β-Thalassemia major. Journal of Herbal Medicine, 21, Article 100324. https://doi.org/10.1016/j.hermed.2019.100324
55.
WangC. W. (2025). Writing systematic reviews. In WangC. W. (Ed.), English for medical communication: A guide to course design (pp. 219–238). Taylor & Francis. https://doi.org/10.4324/9781003375654-11
56.
YadavP. K.SinghA. K. (2022). A review of iron overload in beta-thalassemia major, and a discussion on alternative potent iron chelation targets. Plasmatology, 15, 1–11. https://doi.org/10.1177/26348535221103560
57.
YangK.LiuX.PengW.HuaF.LiL.ChenK.ZhangJ.LuoS.LiW.DingY.ChenJ.XiaoJ. (2024). Effects of thalidomide on erythropoiesis and iron homeostasis in transfusion-dependent β-Thalassemia. Mediterranean Journal of Hematology and Infectious Diseases, 16(1), e2024001. https://doi.org/10.4084/MJHID.2024.001
58.
YasaraN.WickramarathneN.MettanandaC.SilvaI.HameedN.AttanayakaK.RodrigoR.WickramasingheN.PereraL.ManamperiA.PremawardhenaA.MettanandaS. (2022). A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia. Scientific Reports, 12(1), 2752. https://doi.org/10.1038/s41598-022-06774-8
59.
ZengX.ZhangY.KwongJ. S. W.ZhangC.LiS.SunF.NiuY.DuL. (2015). The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: A systematic review. Journal of Evidence-Based Medicine, 8(1), 2–10. https://doi.org/10.1111/jebm.12141
